| Overview |
| bs-11776R-FITC |
| UBE3A/E6-AP Polyclonal Antibody, FITC Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human UBE3A/E6-AP |
| 701-800/875 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7337 |
| Nucleus |
| ANCR; Angelman syndrome; AS; CTCL tumor antigen se37 2; E6 AP; E6AP antibody E6AP ubiquitin protein ligase; E6AP ubiquitin protein ligase; E6AP ubiquitin-protein ligase; EPVE6AP; HPVE6A; Human papilloma virus E6 associated protein Angelman syndrome; Human papilloma virus E6 associated protein; Human papillomavirus E6-associated protein; NY REN 54 antigen; NY REN 54 antigen; Oncogenic protein associated protein E6 AP; Oncogenic protein associated protein E6AP; Oncogenic protein-associated protein E6-AP; Renal carcinoma antigen NY REN 54; Renal carcinoma antigen NY-REN-54; UBE 3A; Ube3a; UBE3A protein; UBE3A_HUMAN; Ubiquitin protein ligase E3A; Ubiquitin-protein ligase E3A. |
| E6-associating protein is a component of the ubiquitin-mediated proteolytic pathway, which selectively targets proteins for degradation by the 26S proteasome. Ubiquitin (Ub) is directly conjugated to protein substrates by the transfer of Ub from an E2 ubiquitin conjugating enzyme to the target protein. This conjugation is facilitated by the enzymatic activity of E3 ubiquitin ligase family members such as E6-AP. Several substrates of E6-AP have been identified and include the tumor suppressor protein p53 and the mammalian homolog of Rad23, HHR23A. Previous studies have indicated that E6-AP associates with the human papillomavirus E6 oncogene, which complexes with p53 and thereby potentiates E6-AP mediated ubiquitination of p53. Genetic mutations that impair E6-AP activity result in the accumulation of p53 in the cytoplasm, and, in many instances, these mutations are associated with the development of the rare neurodevelopmental disorder Angelman syndrome (AS), which is characterized by severe motor dysfunction and mental retardation. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz